Global Alopecia Treatment (Hair Loss) Market, By Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia, Non‒Cicatricial Alopecia, Traction Alopecia, Ciatricial Alopecia, Alopecia Totalis, Alopecia Universalis, Others), Treatment (Localized Therapies, Medical Devices, Systemic Therapies, Herbal Treatment, Hair Transplant Services, Low Level Laser Therapy), Drug Type (Topical Agents, Oral Drugs, Injections, Corticosteroids, Immunosuppressants, Minoxidil, Finasteride, Others), Gender (Male, Female), Age Group (Below 18 Years, 18-34 Years, 35-49 Years, Above 50 Years), Form (Topical, Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Drug Stores, Dermatology Clinics, Retail Pharmacy, Online Pharmacy, Others), End-Users (Hospitals, Dermatologic and Trichology Clinics, Aesthetic Clinics, Specialty Clinics, Homecare, Others) – Industry Trends and Forecast to 2030.
Alopecia Treatment (Hair Loss) Market Analysis and Size
Hair loss is on the rise due to poor eating patterns and sedentary lifestyles with each passing decade. In addition, aging, hormonal imbalance, and an increase in chronic diseases like cancer, hypertension, arthritis, and depression, particularly in the middle-aged population, all contribute to hair loss. Nearly 95% of men's hair loss is caused by androgenetic alopecia, according to the American Hair Loss Association. Over 800,000 people worldwide are looking for a cure for hair loss, thus the market sees a surge in technology and treatment in the market in the mentioned forecast period.
Data Bridge Market Research analyses that the alopecia treatment (hair loss) market, valued at USD 3,614.73 million in 2022, will reach USD 6,266.73 million by 2030, growing at a CAGR of 7.12% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Alopecia Treatment (Hair Loss) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia, Non‒Cicatricial Alopecia, Traction Alopecia, Ciatricial Alopecia, Alopecia Totalis, Alopecia Universalis, Others), Treatment (Localized Therapies, Medical Devices, Systemic Therapies, Herbal Treatment, Hair Transplant Services, Low Level Laser Therapy), Drug Type (Topical Agents, Oral Drugs, Injections, Corticosteroids, Immunosuppressants, Minoxidil, Finasteride, Others), Gender (Male, Female), Age Group (Below 18 Years, 18-34 Years, 35-49 Years, Above 50 Years), Form (Topical, Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Drug Stores, Dermatology Clinics, Retail Pharmacy, Online Pharmacy, Others), End-Users (Hospitals, Dermatologic and Trichology Clinics, Aesthetic Clinics, Specialty Clinics, Homecare, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Cipla Inc. (U.S.), Endo International plc (Ireland), Zydus Group (India), Abbott (U.S.), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd. (India), Perrigo Company plc (Ireland), Curallux, LLC. (U.S.), DR. KURT WOLFF GMBH & CO. KG (Germany), WOCKHARDT (India), Sun Pharmaceutical Industries Ltd.(India), Concert Pharmaceuticals. (U.S.), Cipla Inc. (India), DAIICHI SANKYO COMPANY, LIMITED. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Alopecia is a type of hair loss brought on by specific medical conditions or dietary problems. Sedentary lifestyles and poor eating habits are contributing to an increase in hair loss. In addition, aging, hormonal imbalance, and an increase in chronic diseases like cancer, hypertension, arthritis, and depression, particularly in the middle-aged population, all contribute to hair loss.
Alopecia Treatment (Hair Loss) Market Dynamics
Drivers
- Increasing prevalence of alopecia drives the market
The increasing prevalence of alopecia, encompassing conditions like androgenetic alopecia and alopecia areata, is a key driver for the alopecia treatment market. Factors such as genetic predisposition, hormonal imbalances, stress, and lifestyle changes contribute to the rising incidence of hair loss worldwide. As more individuals experience hair loss, there is a growing demand for effective treatment options to address this concern. This drives market growth as pharmaceutical companies and healthcare providers focus on developing and offering innovative solutions to meet the needs of the growing patient population seeking treatment for various forms of alopecia.
- Aging population drives the market
The aging population is a significant driver for the growth of the alopecia treatment market. Hair loss is commonly associated with aging, and as the global population continues to age, the prevalence of age-related hair loss is expected to increase. With more individuals in older age groups experiencing hair loss, there is a greater demand for effective treatment options to address this concern. This demographic trend provides an opportunity for pharmaceutical companies and healthcare providers to develop and offer specialized treatments tailored to the unique needs of the aging population, driving the expansion of the alopecia treatment market.
Opportunities
- Rising disposable income creates opportunities in the market
The rising disposable income and changing lifestyles present a significant opportunity for the alopecia treatment market. As individuals have more disposable income, they are increasingly willing to invest in personal care, including treatments for hair loss. With a growing emphasis on appearance and self-esteem, people are seeking effective solutions to address hair loss concerns. This increased demand creates an opportunity for companies in the alopecia treatment market to provide innovative and advanced treatment options that cater to the evolving needs and preferences of consumers. By capitalizing on this opportunity, businesses can tap into a growing market and further create growth and development in the alopecia treatment industry.
- Increasing investment in research and development creates an opportunity to grow
The increasing investment in research and development presents a significant opportunity for the alopecia treatment market. Pharmaceutical companies and research institutions are dedicating resources to developing innovative treatment approaches, such as novel drug compounds, stem cell therapies, and regenerative medicine techniques. These investments aim to bring new and improved treatment options to individuals experiencing hair loss. By leveraging advancements in scientific understanding and technology, companies can introduce more effective and targeted treatments, enhancing patient outcomes and satisfaction. This opportunity allows businesses to differentiate themselves in the market, attract a larger customer base, and capitalize on the demand for advanced alopecia treatments, ultimately creating market growth and expansion.
- Technological advancements in treatment options create expansion
Technological advancements in alopecia treatment options present a significant opportunity for market growth. Innovations such as hair transplant procedures, laser therapies, and topical medications have revolutionized the field by offering more effective and customizable solutions. Hair transplant procedures provide long-lasting results with natural-looking outcomes. Laser therapies stimulate hair growth and improve the overall condition of the scalp. Topical medications, including minoxidil and finasteride, have shown efficacy in promoting hair regrowth. These advancements address the growing demand for safe and efficient treatments, attracting more individuals seeking effective solutions for hair loss.
Restraints/Challenges
- High treatment costs impede the market growth
The high treatment costs associated with certain alopecia treatment options, like hair transplant procedures, act as a significant restraint on market growth. The expense of these treatments can deter individuals from seeking professional help, especially those with limited financial resources. Inaccessibility due to high costs prevents a substantial portion of the population from accessing effective treatments, limiting market growth potential.
- Limited effectiveness of treatments restricts the market growth
The limited effectiveness of alopecia treatments is a significant restraint on market growth. Despite the availability of various treatment options, the outcomes can vary widely among individuals. Some may experience minimal or no regrowth of hair, leading to dissatisfaction and reduced trust in treatment efficacy. This limitation hinders market growth as individuals may become hesitant to invest in treatments that may not deliver satisfactory results.
- Side effects and safety concerns limit the market growth
Side effects and safety concerns associated with alopecia treatments present a significant restraint on market growth. Medications like minoxidil and finasteride, commonly used for hair loss, can cause scalp irritation or other adverse reactions in certain individuals. These potential side effects raise safety concerns and may discourage individuals from pursuing treatment or continuing its use. For the market to expand, patient trust in the safety and acceptability of treatments is essential.
This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alopecia treatment (hair loss) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2021, Ritlecitinib's successful phase 2b/3 trial for the treatment of alopecia was announced by Pfizer. The Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family are the first targets of a new class of covalent kinase inhibitors, which include ritlecitinib. Ritlecitinib is being tested as a treatment for alopecia to stop the immune cells and signaling molecules that are a major cause of hair loss from functioning.
Global Alopecia Treatment (Hair Loss) Market Scope
The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, drug type, gender, age group, form, distribution channel, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Alopecia Areata
- Cicatricial
- Traction
- Androgenetic Alopecia
- Non‒Cicatricial Alopecia
- Traction Alopecia
- Ciatricial Alopecia
- Alopecia Totalis
- Alopecia Universalis
- Others
Treatment
- Localized Therapies
- Medical Devices
- Systemic Therapies
- Herbal Treatment
- Hair Transplant Services
- Low Level Laser Therapy
Drug Type
- Topical Agents
- Creams
- Oils
- Gels
- Shampoo
- Lotion
- Foam
- Oral Drugs
- Injections
- Platelet Rich Plasma
- Steroid Injections
- Injectable Filler
- Corticosteroids
- Immunosuppressants
- Minoxidil
- Finasteride
- Others
Gender
- Male
- Female
Age Group
- Below 18 Years
- 18-34 Years
- 35-49 Years
- Above 50 Years
Form
- Topical
- Oral
- Parenteral
Distribution Channel
- Hospital Pharmacy
- Drug Stores
- Dermatology Clinics
- Retail Pharmacy
- Online Pharmacy
- Others
End-Users
- Hospitals
- Dermatologic and Trichology Clinics
- Aesthetic Clinics
- Specialty Clinics
- Homecare
- Others
Alopecia Treatment (Hair Loss) Market Regional Analysis/Insights
The alopecia treatment (hair loss) market is analysed and market size insights and trends are provided by disease type, treatment, drug type, gender, age group, form, distribution channel, and end-users as referenced above.
The countries covered in the alopecia treatment (hair loss) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market and will continue to flourish its trend of dominance during the forecast period. The major factors attributable to the region’s dominance are is likely to dominate the market for alopecia (hair loss) treatments. The common form of alopecia and the effects that people with alopecia experience have driven the regional market. The primary driver of the regional market's growth, however, is a market that is expanding and attracting new competitors.
Asia-Pacific will undergo the highest growth rate during the forecast period owing to rising use of hair care treatments for alopecia and an increase in its prevalence. Moreover, improving the healthcare regulatory scenario in developing countries is expected to attract international players to invest and capitalize on the available market opportunities
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis
The alopecia treatment (hair loss) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to alopecia treatment (hair loss) market.
Some of the major players operating in the alopecia treatment (hair loss) market are:
- Johnson & Johnson Private Limited (U.S.)
- GlaxoSmithKline plc U.K.)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Cipla Inc. (India)
- Endo International plc (Ireland)
- Zydus Group (India)
- Abbott (U.S.)
- Aurobindo Pharma (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Perrigo Company plc (Ireland)
- Curallux, LLC. (U.S.)
- DR. KURT WOLFF GMBH & CO. KG (Germany)
- WockhardtHospitals (India)
- Sun Pharmaceutical Industries Ltd.(India)
- Concert Pharmaceuticals. (U.S.)
- Cipla Inc. (India)
- DAIICHI SANKYO COMPANY, LIMITED. (Japan)
SKU-